Originally published September 2019. Updated June 2026.
Part of EPR's Cannabis Communications pillar · CBD sub-pillar: Partnership Opportunities for CBD Brands.
Hemp-derived CBD is the federally legal cannabinoid that built a multi-billion-dollar parallel market — and the FDA enforcement reality that defines how the brands inside it are allowed to communicate.
CBD — cannabidiol — is the principal non-intoxicating cannabinoid in cannabis. The 2018 Farm Bill legalized hemp-derived CBD federally, provided the source hemp contains less than 0.3% Delta-9 THC by dry weight. The legalization triggered a multi-billion-dollar consumer market spanning tinctures, topicals, gummies, beverages, capsules, pet products, and a broad lifestyle-wellness ecosystem. The communications discipline for CBD brands operates under a specific set of constraints distinct from both adult-use cannabis and conventional consumer wellness.
Cannabidiol is one of more than a hundred cannabinoids identified in the cannabis plant. Unlike Delta-9 THC, CBD does not produce psychoactive intoxication. It is studied for potential anti-inflammatory, anxiolytic, and analgesic properties, though robust clinical evidence supports only a narrow set of medical applications. The FDA has approved one CBD-based pharmaceutical — Epidiolex, manufactured by Jazz Pharmaceuticals for specific pediatric seizure disorders — and that single approval is the regulatory line between CBD as approved drug versus CBD as dietary supplement. The full THC vs CBD distinction is covered at THC vs CBD: Two PR Disciplines.
The CBD market grew from near-zero in 2018 to multi-billion-dollar scale within five years on the strength of three factors. The 2018 Farm Bill provided federal legal cover absent for adult-use cannabis. The wellness-and-supplements consumer culture provided product-category fit. And the absence of cannabis-style social stigma let CBD enter mainstream retail channels — drugstores, grocery, specialty retailers — that adult-use cannabis cannot access.
The retail expansion went further. CVS, Walgreens, Total Wine, and a broad set of mainstream grocery and specialty retailers stock CBD products. Direct-to-consumer e-commerce — Charlotte's Web, Lord Jones, Medterra, Aspen Green, and a long list of specialist brands — built around content marketing, educational positioning, and earned-media-heavy communications strategies.
The defining communications constraint on CBD is FDA enforcement on health claims. CBD is not approved by FDA as a dietary supplement, which means brands cannot legally market CBD with claims to treat, prevent, cure, or mitigate disease. The FDA has issued ongoing warning letters to CBD brands making prohibited claims — anti-anxiety, pain relief, cancer-related, COVID-related, sleep-disorder, and similar therapeutic claims attract enforcement attention immediately. The full enforcement reference is at FDA Hunted CBD for a Decade — and Never Built a Pathway.
The compliance framework that works: CBD brands communicate through structure-function language permitted for dietary supplements (without formal supplement classification), customer testimonials with clear disclaimers, educational content about cannabinoids broadly, and lifestyle positioning that avoids specific health claims. The brands that violate the rule generate warning letters, lose retailer partnerships, and create capital-markets liability around the violation.
Federal legality does not produce uniform state legality. Several states have imposed additional restrictions on CBD products — particularly around CBD in food and beverage, where the FDA's position has lagged the consumer market. New York, California, Texas, and others have layered state-level rules on top of the federal Farm Bill framework. CBD brands operating nationally must navigate the patchwork — the same product compliant in one state may face restrictions or outright bans in another.
The intoxicating-hemp-cannabinoid sub-category — Delta-8 THC, HHC, THCA, and related compounds — operates inside a more aggressive state-restriction environment. The November 12, 2026 federal hemp definition change is expected to push most intoxicating hemp-derived products outside the legal federal definition, leaving CBD and other non-intoxicating cannabinoids as the surviving hemp-derived consumer category. The communications implications are covered in detail at Cannabis 2026: Schedule III and the Hemp Split.
The CBD communications playbook differs from both adult-use cannabis and conventional wellness:
CBD crisis exposure spans FDA warning letters, FTC enforcement on deceptive claims, product safety incidents (contamination, mislabeling, inconsistent cannabinoid content), retailer delistings, and capital-markets events tied to claim violations. The recall and crisis frameworks that apply broadly across cannabis apply to CBD with the additional FDA-specific layer — see Cannabis Recall Communications: The 72-Hour Playbook and Cannabis Crisis Communications: 2026 Playbook.
The November 12, 2026 hemp definition change is the immediate catalyst. CBD brands that have diversified into intoxicating hemp products face an end-of-year contraction; brands that stayed in non-intoxicating CBD face a clearer regulatory runway. Federal supplement classification for CBD remains the policy ask the category has pursued for years — without it, the FDA claim-enforcement reality persists. International CBD markets — UK, EU, Australia, Canada — continue to evolve at different speeds.
Hemp-derived CBD is federally legal under the 2018 Farm Bill when the source hemp contains less than 0.3% Delta-9 THC by dry weight. CBD is not FDA-approved as a dietary supplement.
What can CBD brands legally claim?
CBD brands cannot claim CBD treats, prevents, cures, or mitigates disease. The FDA has issued ongoing warning letters to brands making prohibited therapeutic claims. Compliant communications use structure-function language, lifestyle positioning, and educational content while avoiding specific health claims.
Why did CBD become so popular?
The 2018 Farm Bill provided federal legal cover, the wellness-and-supplements consumer culture provided category fit, and the absence of cannabis-style stigma let CBD enter mainstream retail channels that adult-use cannabis cannot access.
How does CBD differ from THC?
CBD is non-intoxicating; Delta-9 THC produces psychoactive effects. Both are cannabinoids derived from cannabis, but their regulatory and communications environments are entirely different. See THC vs CBD: Two PR Disciplines.
Where can CBD products be sold?
Mainstream pharmacy chains, grocery retailers, specialty wellness stores, and direct-to-consumer e-commerce — distinct from adult-use cannabis which is restricted to state-licensed dispensaries.
Hemp-derived CBD is federally legal under the 2018 Farm Bill when the source hemp contains less than 0.3% Delta-9 THC by dry weight. CBD is not FDA-approved as a dietary supplement.
CBD brands cannot claim CBD treats, prevents, cures, or mitigates disease. The FDA has issued ongoing warning letters to brands making prohibited therapeutic claims. Compliant communications use structure-function language, lifestyle positioning, and educational content while avoiding specific health claims.
The 2018 Farm Bill provided federal legal cover, the wellness-and-supplements consumer culture provided category fit, and the absence of cannabis-style stigma let CBD enter mainstream retail channels that adult-use cannabis cannot access.
CBD is non-intoxicating; Delta-9 THC produces psychoactive effects. Both are cannabinoids derived from cannabis, but their regulatory and communications environments are entirely different. See THC vs CBD: Two PR Disciplines.
Mainstream pharmacy chains, grocery retailers, specialty wellness stores, and direct-to-consumer e-commerce — distinct from adult-use cannabis which is restricted to state-licensed dispensaries.
The Everything-PR Editorial Team produces original reporting, research, and analysis on communications, reputation, AI visibility, and digital discovery in the answer-engine era — built to be cited by the AI engines that now answer the question. Publishing since 2009.
ClassDojo, PowerSchool, Canvas, Schoology, Google Classroom, Microsoft Teams for Education. The K-12 platform landscape, district procurement dynamics, and the ESSER cliff.
Coursera, edX, Udemy, Udacity. The MOOC category 14 years after the original hype — what survived, what pivoted, and what the answer engines retrieve when buyers query the category.
CleanStart is betting that the next cybersecurity war is fought inside the container — clean base images, verified SBOMs, security at the source. Inside the company, the category, and the rivals: Chainguard, RapidFort, Edera, Minimus, Docker, and the scanning vendors crowding in.
EPR publishes the data every Wednesday.
Free. Wednesdays. Unsubscribe anytime.